Novo Nordisk Shares Face Pressure After Weight-Loss Drug Trial Disappoints

Novo Nordisk's obesity drug candidate CagriSema failed to match Eli Lilly's Tirzepatide in a head-to-head trial, shaking investor confidence and triggering analyst downgrades.

Investor confidence in Novo Nordisk's ability to lead the next wave of obesity treatments has been shaken. The Danish pharmaceutical giant's key pipeline candidate, CagriSema, failed to demonstrate non-inferiority against rival Eli Lilly's Tirzepatide in a head-to-head clinical study. This outcome directly challenges the market's expectation that Novo would maintain its momentum following the success of Wegovy.

A Direct Clinical Comparison Yields a Clear Result

The Phase 3 trial, known as REDEFINE 4, involved 809 randomized participants with obesity. After 84 weeks, patients receiving 2.4 mg of CagriSema achieved an average 23% reduction in body weight. This result fell short of the 25.5% average weight loss recorded in the cohort taking 15 mg of Tirzepatid, the active agent in Lilly's Mounjaro and Zepbound.

Novo Nordisk confirmed the candidate did not meet the trial's primary endpoint. Martin Holst Lange, the company's head of research, noted the open-label design—where participants were aware of which treatment they received—could have introduced bias into the results.

Market and Analyst Reaction Is Swift and Severe

The market response has been pronounced, with the direct comparison serving as a stark reality check. The stock recently traded at 32.78 €, marking a 52-week low. Its decline over the past 7 days now totals 21.26%.

Financial analysts have moved quickly to adjust their forecasts. According to Reuters, Barclays slashed its peak sales estimate for CagriSema dramatically to $2 billion USD, down from a previous projection of $12 billion USD. Morningstar reduced its fair value estimate for Novo Nordisk to 343 Danish Krone (DKK), having previously cut it to 372 DKK from 423 DKK in early February. Furthermore, Morningstar lowered its 2035 revenue forecast for CagriSema from 85 billion DKK to 50 billion DKK.

A core rationale behind these downgrades is commercial viability. Without a demonstrated efficacy advantage, analysts argue Novo Nordisk may struggle to persuade physicians and patients to switch from established treatments. Barclays suggested the company may have "little to leverage beyond price" in the upcoming competitive battle.

Pipeline Developments and Regulatory Path Provide Some Balance

Despite the setback, Novo Nordisk did announce positive data elsewhere in its pipeline on Tuesday. A Phase 2 study in China for the triple-agonist UBT251, developed with United Biotechnology, showed a statistically significant mean weight loss of up to 19.7% after 24 weeks. This drug candidate targets GLP?1, GIP, and glucagon receptors simultaneously.

The journey for CagriSema is also far from over. Novo Nordisk submitted the drug for FDA approval in December 2025, with a decision expected by the end of 2026. Additional studies are ongoing, including REDEFINE 11, which will report data in the first half of 2027. A high-dose study is also scheduled for the second half of 2026.